Synthesis and in vitro studies on a potential dopamine prodrug

Pharmazie

Volumn 63, Issue 10, 2008, Pages 704-710

  Giannola, Libero Italo ^a   De Caro, V ^a   Giandalia, G ^a   Siragusa, M G ^a   Lamartina, L ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [2 (3,4 DIHYDROXYPHENYL)ETHYL] 3 PHENYLPROPIONAMIDE; DOPAMINE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; DRUG HALF LIFE; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; RAT;

ANIMALS; BUFFERS; CHEMISTRY, PHYSICAL; DOPAMINE; DRUG DELIVERY SYSTEMS; HUMANS; INDICATORS AND REAGENTS; INTESTINAL MUCOSA; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANES, ARTIFICIAL; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 54149113724     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8585     Document Type: Article

References (39)

1. Abraham MH, Chada S, Mitchell R (1994) Hydrogen bonding. 33 Factors that influence the distribution of solutes between blood and brain. J Pharm Sci 83: 1257-1268.
2. Anderson BD (1996) Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 19: 171-202.
3. Antolin I, Mayo JC, Sainz RM, de los Angeles del Brio M, Herrera F, Martin V, Rodriguez C (2002) Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 943: 163-173.
4. Balimane PV, Chong S, Morrison RA (2000) Current methodologies used for evaluation of intestinal permeability and absorption. J Pharmacol Toxicol Meth 44: 301-312.
5. Ballabh P, Braun A, Nedergaard M (2004) The blood-brain barrier: an overview. Structure, regulation, and clinical implications. Neurobiol Disease 16: 1-13.
6. Bickel U, Yoshikawa T, Pardridge WM (2001) Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 46: 247-279.
7. Bodor N, Farag HH, Brewster ME (1981) Site-specific, sustained release of drugs to the brain. Science 214: 1370-1372.
8. Bodor N, Buchwald P (1999) Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 3: 229-254.
9. Borgman RJ, McPhillips JJ, Stitzel RE, Goodman IJ (1973) Synthesis and pharmacology of centrally acting dopamine derivatives and analogs in relation to Parkinson's disease. J Med Chem 16: 630-633.
10. Casagrande C, Ferrari G (1973) 3,4-O-Diacyl derivatives of dopamine. Farmaco 28: 143-148.
11. Chen HJC, Applewhite T, Jayachandran B, Kirk KL (1998) Synthesis of 4,6-difluoro-5-hydroxy-(α-methyl)tryptamine and 4,6-difluoro-5-hydroxy- (β-methyl)tryptamine as potential selective monoamine oxidase B inhibitor. J Fluorine Chem 92: 41-44.
12. Crivori P, Cruciani G, Carrupt PA, Testa B (2000) Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 43: 2204-2216.
13. Di Stefano A, Sozio P, Cerasa LS (2008) Antipakinson prodrugs. Molecules 13: 46-68.
14. Egleton RD, Davis TP (1997) Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18: 1431-1439.
15. Fernandez C, Nieto O, Rivas E, Montenegro G, Fontenla JA, Fernàndez-Mayoralas A (2000) Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr Res 327: 353-365.
16. Fernández C, Nieto O, Fontenla JA, Rivas E, de Ceballos ML, Fernández-Mayoralas A (2003) Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1. Org Biomol Chem 1: 767-771.
17. Ghersi-Egea JF, Leninger-Muller B, Suleman G, Siest G, Minn A (1994) Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J Neurochem 62: 1089-1096.
18. Giannola LI, De Caro V, Giandalia G, Siragusa MG, Campisi G, Florena AM, Ciach T (2007) Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur J Pharm Biopharm 65: 238-246.
19. Gimenez F, Fernandez C, Mabondzo A (2004) Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr 36: 649-658.
20. Huber JD, Egleton RD, Davis TP (2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24: 719-725.
21. Klegeris A, Korkina LG, Greenfield SA (1995) Autoxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solution. Free Radic Biol Medic 18: 215-222.
22. Levin VA (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23: 682-684.
23. Lo EH, Singhal AB, Torchilin VP, Abbott NJ (2001) Drug delivery to damage brain. Brain Res Rev 38: 140-148.
24. McOmie JFW, Watts ML, West DE (1968) Demethylation of aryl methyl ethers by boron tribromide. Tetrahedron Lett 24: 2287-2292.
25. Oldendorf WH, Crane PD, Braun LD, Wade LA, Diamond JM (1983) Blood-Brain Barrier transport of basic amino acids is selectively inhibited at low pH. J Neurochem 40: 797-800.
26. Pahwa R, Koller WC (1998) Advances in the treatment of Parkinson's disease. Drugs Today 34: 95-105.
27. Pardridge WM (1977) Kinetics of competitive inhibition of a neutral amino acid transport across the blood-brain barrier. J Neurochem 28: 103-108.
28. Pardridge WM (1995) Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev 15: 5-36.
29. Ragot JP, Steeneck C, Alcaraz ML, Taylor RJK (1999) The synthesis of 1,8-dihydroxtnaphtalene-derived natural products: palmarumycin CP1, palmarumycin CP2, palmarumycin C11, CJ-12,371, deoxypreussomerin A and novel analogues. J Chem Soc, Perkin Trans I, 1073-1082.
30. th Ed, Pharmaceutical Press, London, UK, p. 844.
31. Scherrmann JM (2002) Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol 38: 349-354.
32. Slebioda M, Wodecki Z, Kolodziejczyk AM (1990) Formation of optically pure N-acyl-N,N′-dicyclohexylurea in N,N′-dicyclohexyl-carbodiimide- mediated peptide synthesis. Int J Pept Protein Res 35: 539-541.
33. th ed., McGraw-Hill Companies, New York, p. 503-519
34. Terasaki T, Tsuji A (1994) Drug delivery to the brain utilizing blood-brain barrier transport systems. J Control Release 29: 163-169.
35. Terland O, Flatmark T, Tangerås A, Gronberg M (1997) Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species. J Mol Cell Cardiol 29: 1731-1738.
36. Tolosa E, Marti MJ, Valldeorioia F, Molinuevo JL (1998) History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 50: S2-S10.
37. th Ed., Lippincott Williams and Wilkins, Philadelphia, p. 1341-1342.
38. Wolburg H, Lippoldt A (2002) Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc Pharmacol 38: 323-337.
39. Zhu C, Jiang L, Chen TM, Hwang KK (2002) A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37: 399-407.